LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
Healthcare
$3.34 -6.62%
-$0.42 today
- Market cap
- $104.94M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
52W Low $5.85High $50.40
Volume 0.64M
Average 0.89M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$69.17M
FY 2025 · Annual
Investing Cash Flow
-$75.67M
FY 2025 · Annual
Financing Cash Flow
$149.75M
FY 2025 · Annual
-24.8% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.76M) | (101.05M) | (69.97M) | (49.77M) | (82.13M) |
| Depreciation & Amortization | 734K | 8.35M | 15K | 58K | (3.12M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 1.34M | 6.37M | 12.55M |
| Change in Working Capital | (2.5M) | (7.21M) | 9.41M | (13.09M) | 3.25M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (329K) |
| Inventory | 0 | 0 | 0 | 0 | (4.28M) |
| Accounts Payables | 1.83M | 194K | 856K | (4.28M) | (90K) |
| Other Working Capital | (4.32M) | (7.4M) | 8.55M | (8.81M) | 7.95M |
| Other Non-Cash Items | 19.67M | 11.93M | (1.18M) | (2.95M) | 279K |
| Operating Cash Flow | (52.85M) | (87.98M) | (60.38M) | (59.39M) | (69.17M) |
| Capital Expenditures | (5.74M) | (6.59M) | (30K) | (468K) | (827K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (405.52M) | (52.09M) | (241.91M) | (280.8M) |
| Sales of Investments | 0 | 170.25M | 22.5M | 87.9M | 205.96M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (5.74M) | (241.86M) | (29.62M) | (154.48M) | (75.67M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 417.16M | 676K | 203K | 79.51M | 149.75M |
| Common Stock Repurchased | 0 | (79K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 306K | 0 | (2.48M) | 119.49M | 0 |
| Financing Cash Flow | 417.47M | 597K | 80.7M | 199M | 149.75M |
| Effect of Forex Changes | (1.72M) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 357.16M | (329.25M) | (9.3M) | (14.87M) | 4.91M |
| Free Cash Flow | (58.59M) | (94.57M) | (60.41M) | (59.86M) | (70M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$82.1M
+ D&A-$3.1M
+ Stock-Based Comp$12.5M
+ Deferred Tax$0
+ Working Capital$3.3M
+ Other Non-Cash$279.0K
= Operating Cash Flow-$69.2M
- Capex-$827.0K
= Free Cash Flow-$70.0M
Analysis
FY2025 free cash flow is -$70.0M. FCF conversion is 85.2% of net income. Operating cash flow was -$69.2M, with capex of -$827.0K. The largest bridge item is Stock-Based Comp at $12.5M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| SC 13G | SC 13G filing | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 |
Does LENZ generate free cash flow?
LENZ Therapeutics, Inc. (LENZ) generated -$70.00M of free cash flow in fiscal 2025.
How much operating cash flow does LENZ produce?
Operating cash flow was -$69.17M, before capital expenditures of $827,000.00.
Continue the stock analysis
Jump to another research area for this company.